

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

TAUNS Laboratories, Inc.

Announcement of Conclusion of License Agreement with First Screening Corp.

IZUNOKUNI, Japan, October 24, 2024 - TAUNS Laboratories, Inc. (Headquarters: Izunokuni-shi, Shizuoka, Japan; President and CEO: Masaki Nonaka; Securities Code: 197A; hereinafter referred to as "the Company") announces that it has concluded a license agreement with First Screening Corp. (Headquarters: Shibuya-ku, Tokyo, Japan; President: Yohei Kanazawa; hereinafter referred to as "FSC"), related to electrochemical detection technology owned by FSC.

As one of the largest companies in the field of infectious disease diagnosis, the Company manufactures and sells in vitro diagnostic products based on various diagnostic technologies in Japan and abroad.

Currently, our main products are antigen test kits for respiratory infections, but as part of our future growth strategy, we are developing technologies to expand into fields other than respiratory infections, such as chronic diseases.

Through this license agreement, the Company has obtained the right to use FSC's electrochemical detection technology in the fields of cardiovascular disease testing, renal disease testing and various infectious disease testing. FSC is a startup company in which the Company has invested, and we have been working on proof of concept in several fields. With the execution of this license agreement, the Company plans to accelerate product development in the aforementioned fields.

Mr. Nonaka, President and CEO of TAUNS, commented on the license agreement as follows.

"Our company has positioned the expansion of our business into fields other than respiratory infection testing as one of our key management strategies. We believe that the conclusion of this license agreement with FSC will lead to the launch of new products that enable minimally invasive and rapid testing in a variety of settings, including not only medical institutions but also the home, especially in the field of chronic diseases. This will steadily advance our company's management strategy. From now on, we will work with FSC to develop products in each target field and aim to further increase our corporate value."

About TAUNS:

Founded in 1987 in Numazu City, Shizuoka, Japan, TAUNS is an R&D-oriented manufacturer with strengths in diagnostic technology. TAUNS' corporate slogan is "Peace of mind through diagnostic technology." TAUNS has been providing antigen test kits to the world, mainly in the field of respiratory infectious diseases, utilizing its long-standing know-how. In recent years, through capital and business alliances with several bio-ventures, we have been working to solve problems in the fields of disease



prevention, pre-symptomatic disease and chronic disease diagnosis. For more information, please visit our website at https://www.tauns.co.jp/en/.

About FSC:

FSC is a startup company working on the development of simple test kits with the mission of "Making the 'First Screening' for Pre-Symptomatic Disease Easier." In response to the need for disease prevention, FSC provides services that support personal healthcare, such as simple test kits that can easily check physical conditions and health improvement programs, to help people lead rich lives. For more information, please visit their website at https://first-screening.com/.

The purpose of this release is to provide our stakeholders with the latest information related to our company. Although it may contain information on our products and research and development, it is intended to disclose our management information and is not intended as promotion, advertisement, or medical advice regarding our products.

For inquiries regarding this press release, please contact: TAUNS Laboratories, Inc. General Affairs Department TEL: +81-55-957-3090 E-mail: kouhou@tauns.co.jp